Petros Grivas, MD, PhD, joins The Uromigos to discuss the use of antibody drug conjugates in bladder cancer. A summary of the prostate and bladder cancer session of the Conversations & Trending Topics in GU Cancers conference. Sam Chang, MD, MBA, joins The Uromigos to discuss the results of IL-15RαFc superagonist N-803 for papillary NMIBC. Is cisplatin any different from carboplatin in advanced bladder cancer? The Uromigos debate the topic with Matt Galsky, MD. Dr. Andrea Necchi describes his recent phase 2 study on the use of neoadjuvant pembrolizumab and nab-paclitaxel for MIBC. The Uromigos chat with Cora Sternberg on her paper on FGFR inhibition in advanced urothelial cancer. John Kelly summarizes a recent paper published in JAMA that describes the benefits of robotic surgery versus open cystectomy. Cora Sternberg, MD, discusses her career that has spanned multiple continents. Syed Hussain and Sam Funt describe their studies on this topic. Matt Galsky and Tom Powles take the FDA and EMA approach respectively concerning adjuvant nivolumab for bladder cancer. Cisplatin-based combination chemotherapy is considered standard of care in mUC, but many patients are deemed ineligible. Dr. Jonathan Rosenberg describes the results of this positive randomized phase 2 trial. Dr. Joaquim Bellmunt gives an overview of the updated ESMO guidelines on bladder cancer. Jonathan Rosenberg discusses what happened in the world of bladder cancer during 2021 and what to look out for in 2022. Dr. Arjun Balar discusses bladder cancer, clinical trials involving pembrolizumab, and his career transition. Dr. Sarmad Sadeghi discusses exciting data about a novel compound in urothelial cancer with Brian and Tom. Dr. Jonathan Rosenberg gives an overview of the NORSE Study. Dr. Dean Bajorin discusses developments in bladder and collaboration in testis cancer. Dr. Ashish Kamat walks through ongoing issues around surgery in urothelial cancer at EAU 2021. Join the debate around pembrolizumab monotherapy in initial treatment of cisplatin-ineligible metastatic urothelial cancer.